Educational material

The use of the PCA3 Assay when deciding on biopsy in a man with an elevated PSA level and a concomitant urinary condition; Patient case from Prof. A. Stenzl

Submitted by Ismar Healthcare on 2009/04/02

The use of the PCA3 Assay when deciding on biopsy when there is a family history of prostate cancer; patient case from Prof. B. Tombal

Submitted by Ismar Healthcare on 2009/04/02

The use of the PCA3 Assay when deciding on repeat biopsy; Patient case from Prof. A. Stenzl

Submitted by Ismar Healthcare on 2009/04/02

The use of the PCA3 Assay when deciding on repeat biopsy; Patient case from Prof. A. Stenzl

Submitted by Ismar Healthcare on 2009/04/02

The PCA3 Assay; how is it used in clinical practice? A presentation of patient cases

Submitted by Ismar Healthcare on 2009/04/03

Prostate Cancer Antigen 3 (PCA3) is an independent and significant predictor for pathologically insignificant Prostate Cancer (PCa) in men undergoing radical prostatectomy

This poster was presented by Dr. Ward at the 24th annual congress of the European Association of Urology (EAU), 17-21 March 2009 in Stockholm, Sweden.

Submitted by Ismar Healthcare on 2009/04/02

The use of PCA3 Assay when deciding on therapy when prostate cancer has been detected. Patient case from Prof. B. Tombal

Submitted by Ismar Healthcare on 2009/04/02

The use of the PCA3 Assay when deciding on repeat biopsy; Patient case from Dr. A. de la Taille

Submitted by Ismar Healthcare on 2009/04/02

PCA3 shows significant association to prostate cancer volume (PCaV) but no correlation to total prostate volume or serum PSA and separates pathologically insignificant from significant prostate cancer (PCa) in men undergoing radical prostatectomy

This poster was presented by Dr. Chun at the 24th annual congress of the European Association of Urology (EAU), 17-21 March 2009 in Stockholm, Sweden

Submitted by Ismar Healthcare on 2009/09/17

Search results